WO2015186962A1 - Composition for alleviating atopic dermatitis, using fermented green tea extract - Google Patents

Abstract

A composition for alleviating atopic dermatitis, using a fermented green tea extract, is disclosed. Particularly, disclosed is a composition for alleviating atopic dermatitis, using a fermented green tea extract alleviating the symptoms of atopic dermatitis such as erythema, hemorrhage, dryness, scarring, lichenification and erosin when administered to laboratory animals in which atopic dermatitis is induced by 2,4-dinitrochlorobenzene (DNCB), which is an immunity disruptor.

Description

Composition for improving atopic dermatitis using fermented green tea extract

The present invention relates to a composition for improving atopic dermatitis using fermented green tea extract.

Atopic dermatitis is an inflammatory disease caused by continuous exposure to foreign antigens. About 10-20% of the world suffers from atopic dermatitis (Tanabe, W., T. etl al., Biochem. Biophys. Res) Commun. 2002. 293: 1348-1353.). The number of atopic dermatitis patients in adolescents is increasing, with 19.2% of children suffering from atopic dermatitis in children between 1 and 5 years old in Korea. The cost of atopic disease medical treatment amounted to KRW 616.1 billion in 2010 (2011, National Assembly Labor Commissioner's Commission), socioeconomic costs are also increasing.

Atopic dermatitis is a chronic inflammatory skin disease mainly accompanied by itching and inflammation (Jiang, J. et al., J Dermatol Sci. 2009 Oct; 56 (1): 37-42). Although it is not clear, genetic factors, immunological factors, and environmental factors are known to occur in combination. The immunological characteristics reported so far in the development of atopic dermatitis include increased secretion of IgE antibodies and IL-4 cytokine and decreased secretion of IFN-γ cytokine in the early stages of disease. Secrete IL-4, IL-5 and IL-13 cytokine (Akdis M et al., J Immunol. 1997 Nov 1; 159 (9): 4611-9.) To allow naive CD4 + T cells to differentiate into Th 2 cells Regulates B cell activation and increases IgE secretion. Therefore, the levels of IL-4, IL-5 and IL-13 cytokine and IgE in the blood of atopic dermatitis patients are abnormally high (Del Prete G et al., J Immunol. 1988 Jun 15; 140 (12): 4193 -8 .; Punonen J et al., Proc Natl Acad Sci US A. 1993 Apr 15; 90 (8): 3730-4.). In addition, Th 1 type cytokines such as IFN-γ and IL-12 are reduced. On the other hand, in late chronic atopic dermatitis, the expression level of IFN-γ cytokine is increased by secondary microbial infection, and Th 1 cell immune response is increased. IFN-γcytokine activates macrophages and NK cells, and activated macrophages secrete cytokines such as TNF-α IL-6 and IL-1β to promote apoptosis of keratinocytes and invade skin tissues. (Homey B et al., J Allergy Clin Immunol. 2006 Jul; 118 (1): 178-89.).

Recently, damage to the skin barrier as well as immunological mechanisms have emerged as a major factor for worsening atopic dermatitis. The outermost stratum corneum of the epidermis is formed from keratinocytes and consists of differentiated keratinocytes and the surrounding lipid layer. These skin barriers are easily damaged by endogenous diseases such as lifestyles such as excessive washing or bathing, environmental factors such as dry air and pollutants, and degradation of lipid synthesis ability of keratinocytes, resulting in atopic dermatitis. Atopic dermatitis thus exhibits symptoms such as lichenitis, tearing and drying. In addition, pruritus occurs throughout the acute and chronic periods, which is important in treating atopic dermatitis because scratching causes secondary skin symptoms such as wounds and secondary infections.

Accordingly, in atopic dermatitis experiments, not only the production of immune substances in the blood but also skin models using animal models such as skin stimulation model, diet induction model, environmental induction model, and ovalbumin skin sensitization model are used. . Generally, Ovalbumin skin sensitization model and skin stimulation model are used a lot, but Ovalbumin skin sensitization model takes longer than chemical skin stimulation model, and the actual dermatitis symptoms are difficult to see with eyes. Therefore, skin stimulation model tends to be preferred. Skin irritation model is a method of inducing atopic dermatitis by using chemicals (DNCB: dintrochlorobenzene, DNFB: dinitrofluorobenzene, PiCl: picryl chloride), which is an acute atopic dermatitis model that can cause dermatitis in a relatively rapid period. It is useful for research because it has the advantage of visually checking the thyroid and blisters.

Currently, steroids that suppress inflammatory reactions and cytokine production are mainly used for the treatment of atopic dermatitis, but the use of nonsteroidal drugs has recently increased due to various side effects such as skin atrophy and the possibility of growth delay. . However, nonsteroidal drugs also have a variety of side effects such as erythema, itching, swelling, soreness, and thyroiditis and weakened immunity, making it difficult to treat fundamental atopic dermatitis (Arellano FM et al., J Invest Dermatol. 2007 Apr 127 (4): 808-16.). Therefore, there is a need for research to find new substances having high therapeutic effects and low side effects from natural products having proven safety.

The present invention has been completed under this background.

An object of the present invention is to provide an atopic dermatitis improving agent composition using a fermented green tea extract.

Other and specific objects of the present invention will be presented below.

As the present invention is confirmed in the following Examples and Experimental Examples, fermented green tea extract obtained by adding 50% ethanol to the green tea prepared by the process of steaming and keeping in mind after fermenting the tea leaves in natural state, and radiated by ultrasonic, Erythema, hemorrhage, dryness, scarring, lichenification, bark when administered to a laboratory animal causing atopic dermatitis with the disturbing substance 2,4-Dinitrochlorobenzene (DNCB) It was completed by confirming that atopic dermatitis symptoms such as erosin are alleviated.

Considering the foregoing, the present invention is characterized in that the fermented green tea extract as an active ingredient.

In the present specification, the "fermented green tea" is taken in the natural state after taking the tea leaves, that is, microorganisms, inoculated microorganisms, temperature, humidity, CO ² in the state without artificial manipulation is applied to the outdoor, indoor or outdoor and indoor (ie, outdoor and indoor Green tea obtained by leaving it to alternately). When referring to the embodiment below, the "fermented green tea" is 1 to 2 hours after the shade in the outdoor natural conditions, until the color of the tea leaves change (the color of the tea leaves until the fruity fragrance is seen as fruit flavor) It may also be 1 to 3 hours) Yangyang (yang 乾) and then it is preferably obtained by drying in the room for 20 to 24 hours through repeated flipping. The fermented green tea thus obtained may be applied before and after the shade in outdoor natural conditions, before and after the shade in the shade, and before and after the shade through repeated flips in the room. Keep in mind that the tea leaves can be more easily dissipated with the tea leaves, which can be more easily dissipated. These keeps in mind can be done by hand or using a commercially available seasoning machine.

In the present specification, "fermented green tea extract" refers to the fermented green tea to be extracted water, methanol, ethanol, butanol lower alcohol having 1 to 4 carbon atoms, methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl Supercritical extraction such as acetate, N, N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), 1,3-butylene glycol, propylene glycol or extracts obtained by leaching using a mixed solvent thereof, carbon dioxide, pentane Means an extract obtained by using a solvent or a fraction obtained by fractionating the extract, and the extraction method may be any method such as cooling, refluxing, heating, ultrasonic radiation, supercritical extraction, etc. in consideration of the polarity, degree of extraction, and degree of preservation of the active substance. The method can be applied. In the case of fractionated extract, the extract is obtained by suspending the extract in a specific solvent and then mixing and standing with a solvent having a different polarity, and extracting the extract sequentially by using the solvents in the order of increasing or decreasing polarity. And fractions obtained by chromatography using properties of size, charge, hydrophobicity, affinity, and the like. In addition, the meaning of the extract includes a concentrated liquid or solid extract from which the extraction solvent is removed by lyophilization, vacuum drying, hot air drying, spray drying, or the like. When referring to the examples below it means that the extract is obtained by immersing the fermented green tea to be extracted in 50% ethanol and emitting ultrasonic waves. Although not shown in the following Examples and Experimental Examples, the present inventors use water as the extraction solvent and ethanol having an ethanol content of 20%, 30%, 40%, 50%, 60%, 70%, 80% and 90%. A mixed solvent of aqueous solution was used and the ultrasonic wave was radiated or heat treated (The mixed solvent of the ethanol aqueous solution was heated in a bath. That is, the fermented tea and the ethanol aqueous solution to be extracted were put in an inner container and water was put in an outer container to 80 ° C. When the extracts were obtained and the total theaflavin content of each extract was measured, the 50% ethanol extracts, which had been irradiated or heated with ultrasound, had a high content of theaflavin, and were stimulated with INF-γ-induced HaCaT cells. When the degree of inhibition of the expression of MDC and TARC is inhibited by treating each extract celestial body, fermented green tea extract is generally superior to the inhibitory activity of MDC and TARC, compared to the non-fermented green tea extract. Also, among the fermented green tea extracts, ultrasonically radiated 50% ethanol extracts were distinctly superior to other extracts. The use of ultrasonically radiated 50% ethanol extract as a sample in the atopic dermatitis animal model experiment of the experimental example below is based on these component analysis results and cell test results. For reference, theaflavin (which refers to theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate, and theaflavin 3,3'-digallate) is used when the tea leaves are naturally fermented. It is known to be formed through the polymerization of polyphenols in tea leaves by the action of phenol oxidase. Antioxidant activity and anti-inflammatory activity have been reported as the causative agents of color and flavor of black tea [Leung et al., J Nutr 2001, 131 ( 9): 2248-51; Sarkar et al., Biochem Biophys Res Commun 2001, 284 (1): 173-8; Yoshino et al., Biol. Pharm Bull. 1994, 17 (1) 146-149. In addition, the MDC and TARC is a chemokine reported to increase the serum concentration significantly in atopic dermatitis patients (Hijnen et. Al., J. Allergy Clin. Immunol. 113 (2) 334-340), atopic dermatitis Cyclosporin A or corticosteroids, which are used as therapeutic agents in patients with atopic dermatitis, have been reported to decrease serum serum levels of MDC and TARC (Y. Shimada et al., J. Dermatol. Sci., 34). , 201-208, 2004), and in vitro experiments, a large amount of MDC and TARC are expressed when hIFN-γ or TNF-α is treated in HaCaT cells, and a substance capable of inhibiting this expression can be used as a therapeutic agent for atopic dermatitis. Yes (Horikawa et. Al., Int. Immunol., 14 (7) 767-773, 2002).

In addition, in the present specification, the meaning of "active ingredient" means a component that can exhibit activity alone or in combination with a carrier having no activity in itself.

Terms not specifically defined herein are in accordance with the Korean dictionary meaning or meaning commonly used in the art.

The composition of the present invention may include the active ingredient in any amount (effective amount) as long as it can exhibit the improvement activity of atopic dermatitis intended to be treated according to the use, formulation, formulation purpose, etc. It will be determined in the range of 0.001% to 15% by weight based on weight. The term "effective amount" as used herein refers to the amount of an active ingredient that can induce improvement, treatment, or suppression / delay of the onset of such pathological symptoms in a mammal, preferably a human subject. Such effective amounts can be determined experimentally within the range of ordinary skill in the art.

Subjects to which the compositions of the invention can be applied (prescribed) are mammals and humans, in particular humans.

The composition of the present invention can be used as a pharmaceutical composition in a specific embodiment.

The pharmaceutical composition of the present invention includes oral formulations (tablets, suspensions, granules, emulsions, capsules, syrups, etc.), parenteral formulations (sterilized), including pharmaceutically acceptable carriers, excipients, etc., in addition to the active ingredients thereof. Aqueous or oily suspensions for injection), topical formulations (solutions, creams, ointments, gels, lotions, patches) and the like.

As used herein, "pharmaceutically acceptable" means that the subject of application (prescription) does not have more toxicity (adequately low toxicity) to which the subject of application (prescription) is adaptable without inhibiting the activity of the active ingredient.

Examples of pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (such as corn starch, potato starch, etc.), cellulose, derivatives thereof (such as sodium carboxymethyl cellulose, ethylcellulose, etc.) malt, gelatin, talc, solids Lubricants (e.g. stearic acid, magnesium stearate, etc.), calcium sulfate, vegetable oils (e.g. peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerin, etc.), alginic acid, emulsifiers (e.g. TWEENS), wetting agents (e.g. Sodium lauryl sulfate), colorants, flavoring agents, tableting agents, stabilizers, antioxidants, preservatives, water, saline, phosphate buffer solutions and the like. Such a carrier may be used by selecting one or more appropriate ones according to the formulation of the pharmaceutical composition of the present invention.

Excipients may be selected and used according to the formulation of the pharmaceutical composition of the present invention, for example, when the pharmaceutical composition of the present invention is prepared with an aqueous suspending agent, suitable excipients are sodium carboxymethyl cellulose, methyl cellulose, hydropropylmethylcellulose And suspending agents and dispersing agents such as sodium alginate and polyvinylpyrrolidone. Suitable excipients when prepared as injections include Ringer's solution, isotonic sodium chloride, and the like.

The pharmaceutical compositions of the present invention may be administered orally or parenterally, and may optionally be administered topically, as in the case of atopic dermatitis compositions.

The daily dosage of the pharmaceutical composition of the present invention is usually 0.001 ~ 150 mg / kg body weight range, it can be administered once or divided into several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as the route of administration, the age, sex, weight of the patient, and the severity of the patient, the dosage may limit the scope of the present invention in any aspect. It should not be understood as.

The composition of this invention can be grasped | ascertained as a food composition in another specific aspect.

The food composition of the present invention may include sweeteners, flavoring agents, bioactive ingredients, minerals, etc. in addition to the active ingredients.

Sweeteners may be used in amounts that give the food a suitable sweet taste, and may be natural or synthetic. Preferably, a natural sweetener is used. Examples of the natural sweetener include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.

Flavoring agents can be used to enhance the taste or aroma, both natural and synthetic. It is the case of using a natural thing preferably. In addition to flavors, the use of natural ones can be combined with nutritional purposes. The natural flavor may be obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or may be obtained from green tea leaves, round leaves, jujube leaves, cinnamon, chrysanthemum leaves, jasmine and the like. In addition, ginseng (red ginseng), bamboo shoots, aloe vera, ginkgo and the like can be used. Natural flavors can be liquid concentrates or solid extracts. In some cases, synthetic flavoring agents may be used, and synthetic flavoring agents may include esters, alcohols, aldehydes, terpenes, and the like.

As the physiologically active substance, catechins such as catechin, epicatechin, gallocatechin, epigallocatechin, vitamins such as retinol, ascorbic acid, tocopherol, calciferol, thiamine, riboflavin, and the like can be used.

As the mineral, calcium, magnesium, chromium, cobalt, copper, fluoride, germanium, iodine, iron, lithium, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, silicon, sodium, sulfur, vanadium, zinc and the like can be used.

In addition, the food composition of the present invention may contain a preservative, an emulsifier, an acidulant, a thickener, and the like, in addition to the sweetener.

Such preservatives, emulsifiers and the like are preferably added and used in very small amounts as long as the use to which they are added can be achieved. By trace amount is meant numerically expressed in the range of 0.0005% to about 0.5% by weight based on the total weight of the food composition.

Examples of preservatives that can be used include sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), and the like.

Emulsifiers that can be used include acacia gum, carboxymethylcellulose, xanthan gum, pectin and the like.

Examples of acidulants that may be used include lead acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, and the like. Such acidulant may be added so that the food composition is at an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to the purpose of enhancing taste.

Thickeners that can be used include suspending implements, sedimenters, gel formers, swelling agents and the like.

In addition, herbal medicines may be added to enhance flavor and taste and to add other functionalities. Herbal medicines that may be added include tofu extract, sokdan extract, antler extract, safflower extract, tosa extract, succinate extract, tortoise extract, and cornus extract , Goji berry extract, licorice extract, Angelica extract, brown root extract, kangjinhyang extract, haphwanpi extract, mountain rump muscle extract, lump extract, ginseng extract and the like can be exemplified.

The composition of this invention can be grasped | ascertained as a cosmetic composition in another specific aspect.

The cosmetic composition of the present invention, in addition to including the active ingredient thereof, may include components conventionally used in the cosmetic composition such as stabilizers, solubilizers, surfactants, vitamins, pigments, and conventional auxiliaries, and carriers. Can be.

The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.

When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as the carrier component, specifically water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, And fatty acid esters of 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.

When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.

When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

The cosmetic composition of the present invention may be prepared according to a method for preparing a cosmetic composition known in the art, including the active ingredient and a carrier component as described above.

As described above, according to the present invention, it is possible to provide an atopic dermatitis improving composition using fermented green tea extract. The compositions of the present invention may be formulated into food compositions, pharmaceutical compositions or cosmetic compositions.

Figure 1 graphically shows the weight change of the experimental animals during the test period.

Figure 2 graphically shows the change in atopic dermatitis evaluation scores of experimental animals during the test period.

Figure 3 is a representative photograph showing the atopic dermatitis state of the experimental animals for each test group during the test period.

Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.

< Example > Preparation of Fermented Green Tea Extract

Selected tea leaves are dried for 1 hour in the open air, and then dried for 2 hours. After changing the color of the tea leaves and the fruity scent, the interior is repeatedly dried at room temperature for 1 hour to 1 hour 30 minutes for 24 hours indoors. ) The dried tea leaves were kept in mind to prepare fermented green tea.

Fermented green tea extract was added to 20 times the weight of 50% ethanol to the fermented green tea, extracted with an ultrasonic extractor (37 kHZ, 470W, 3A) for 1 hour, filtered through a filter paper and concentrated in vacuo to prepare a powdered fermented green tea extract.

< Experimental Example > Atopic Dermatitis Improvement Activity Test of Fermented Green Tea Extract

(1) Skin irritation Atopic dermatitis animal model

It is a human atopic dermatitis-like model that develops acutely in infancy and chronically from adolescence to adulthood. In vivo, using animal model of skin irritation atopic dermatitis using immune disturbance chemical 2,4-Dinitrochlorobenzene (DNCB) Atopic dermatitis activity was evaluated.

In this experiment, we evaluated the inhibition and activity of atopic related factors using skin stimulation atopic dermatitis animal model for more accurate and efficient evaluation of atopic dermatitis.

-Used animals

(1) Species and strains: Balb / c mouse

(2) Supply and producer

   Name: Daewoo Biolink

   Address: 113, Daeyari, Samsung-myeon, Eumseong-gun, Chungbuk

(3) Reason for selecting animals:

   Balb / c mice are recommended for the evaluation of atopic dermatitis and are widely used for atopic dermatitis efficacy evaluation. Balb / c species have abundant basic test data to facilitate the interpretation or evaluation of test results.

 (4) Age (sex) and weight range at the time of acquisition: 6 weeks (male), 20-23g

 (5) Purification Method and Period

    General symptoms are observed once daily during the week of quarantine and purifying. Select healthy animals suitable for testing by weighing at the time of import, quarantine, and at the end of the acclimatization period.

 (6) group separation

   The body weight was measured on the day before administration, and the excel program was used to separate the mean and standard deviation between groups.

 (7) individual identification

    Individual identification is based on notation and breeding box individual identification card.

-Environmental conditions

  (1) Temperature and humidity range: temperature 22, relative humidity 45%

  (2) Number of ventilation: 10 ~ 15 times / hour

  (3) Illumination time and contrast cycle: 12 hr

  (4) Roughness: 150 ~ 205 Lux

  (5) Noise: 50 dB or less

  (6) Breeding box and breeding density

     Polycarbonate Breeding Box (143 W (mm), Jeung-Do B & P), 3 per cage

  (7) feed and drinking water

     The feed was fed a regular diet, the negative water was filtered and filtered sterilized in a polycarbonate drinking bottle (250 mL) using a filter and an oil sterilizer.

- feed

  (1) General diet: 18% Protein, 2918C (for specific nutritional composition of the feed, see Table 1 below)

  (2) feed and production

     Name: Harlan Laboratories Inc, USA 8520 Allison

     Address: Pointe Bivd, suite 400, Indianapolis, IN 46250

Table 1

(2) Experiment method

Remove the mouse's back from the bottom of the ear to the top of the tail and leave for 24 hours, and then 200 µl of 1.5% DNCB (2,4-dinitrochlorobenzene) solution (acetone: olive oil = 3: 1) was applied to the epilation site, and 3 days After the second coating. From the 7th day after the 1st application, 150 microliters of 0.5% DNCB solutions were apply | coated again three times a week for 3 weeks, and atopic dermatitis was induced. Samples were orally administered once a day for three weeks.

The evaluation was performed by clinical gross evaluation method commonly used in atopic dermatitis. The severity of atopic dermatitis was measured by the sum of the following scores (Clinical dermatitis score test). Evaluation items include erythema, hemorrhage, dryness, scarring, lichenification, erosin, and no symptoms (0 points) for each item. Scores as weak (1 point), moderate (2 points), severe (3 points), and adds up to 6 items for a minimum of 0 (no symptoms) to 18 points (all items with severe symptoms) The evaluation score was given.

The composition of the test group is shown in Table 2 below.

TABLE 2

(3) experimental results

(3-1) weight change

The weight change measured for 3 weeks is shown in FIG. 1. There was no change in body weight for three weeks following the administration of the extract of the example.

(3-2) Change in atopic dermatitis evaluation score

Atopic dermatitis evaluation scores measured for three weeks are shown in FIGS. 2 and 3. Referring to FIG. 2, in the case of DNCB atopic dermatitis-induced group, erythema, psoriasis, soreness, and thyroiditis are developed evenly from 2 weeks after the dermatitis, and the score of about 8 is shown evenly after 3 weeks. While showing a score, in the case of the sample administration group of the embodiment, socre decreases or at least does not increase, it can be seen that there is a marked difference from the PBS administration group (Vehicle).

Claims (5)

1. Fermented green tea extract as an active ingredient,

   The fermented green tea is obtained by leaving the collected tea leaves in a natural state

   Atopic dermatitis improvement composition.
2. The method of claim 1,

   The fermented green tea extract is atopic dermatitis improving composition, characterized in that obtained by adding 50% ethanol to the fermented green tea and ultrasonic spinning.
3. The method of claim 1,

   The composition is a composition for improving atopic dermatitis, characterized in that the pharmaceutical composition.
4. The method of claim 1,

   The composition is a composition for improving atopic dermatitis, characterized in that the food composition.
5. The method of claim 1,

   The composition is a composition for improving atopic dermatitis, characterized in that the cosmetic composition.

Images